EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epithelial HSD11β2 as an immunometabolic checkpoint in head and neck cancer: Restoring local steroid inactivation reinvigorates T cell immunity

Felipe F Lamenza, Puja Upadhaya, Ravi Ramalingam, Sushmitha Jagadeesha, Suvekshya Shrestha, Reegan Kehres, Natalie Kazmierowicz, Sonali Dasari, Shaheer Masood, Kishan Kumar Nyati, Peyton Roth, Natalie Horn und 6 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Felipe F Lamenza und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohi…. Hauptthemen laut MEDLINE: 11-beta-Hydroxysteroid Dehydrogenase Type 2, Head and Neck Neoplasms, T-Lymphocytes, Squamous Cell Carcinoma of Head and Neck. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Cancer Society Inc, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic glucocorticoid (GC) effects in oncology are well recognized; however, the role of local GC metabolism within the tumor microenvironment remains poorly defined. Epithelial 11β-hydroxysteroid dehydrogenase 2 (HSD11β2), which inactivates GCs, may regulate GC-driven immune suppression in head and neck squamous cell carcinoma (HNSCC). We combined clinical survival analyses from an HNSCC cohort (ORIEN) with mechanistic studies in CRISPR/Cas9 Hsd11β2-knockout (KO) cell lines, an epithelial-specific Hsd11β2 conditional KO (eHSD-/-) mouse model, and an orthotopic model with exogenous GC exposure. Immune profiling, GC quantification, and transcriptomic analyses were performed. Apigenin was evaluated as a pharmacologic inducer of HSD11β2. In the retrospective HNSCC cohort, GC (Prednisolone) exposure was associated with inferior overall survival (HR = 2.1, 95% CI 1.3-3.46; p < 0.0001). Loss of epithelial Hsd11β2 increased active GC bioavailability, enhanced tumor proliferation, and suppressed T cell effector function, accompanied by expansion of immunosuppressive myeloid populations. Transcriptomic analyses revealed activation of GC-responsive and pro-tumor pathways with concurrent depletion of lymphocyte activation signatures. Pharmacologic induction of HSD11β2 with apigenin reduced active GC levels, suppressed tumor growth, and restored T cell function. Notably, apigenin retained partial antitumor effects in Hsd11β2 KO models, indicating both HSD11β2 dependent and complementary mechanisms. These findings support a role for local GC metabolism as an immunometabolic checkpoint in HNSCC. In experimental models, restoring epithelial GC inactivation via HSD11β2 reduces immune suppression and restrains tumor progression. Pharmacologic induction of HSD11β2 represents a promising strategy to counter steroid-driven immune evasion and may enhance responses to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

11-beta-Hydroxysteroid Dehydrogenase Type 2Head and Neck NeoplasmsT-LymphocytesSquamous Cell Carcinoma of Head and NeckGlucocorticoidsAnimalsHumansMiceMice, KnockoutCell Line, TumorTumor MicroenvironmentApigeninFemale

Stichwörter der Autor:innen

ChemopreventionGlucocorticoidsHSD11β2Head and neck squamous cell carcinomaImmunometabolism and tumor microenvironment

Substanzen

11-beta-Hydroxysteroid Dehydrogenase Type 2ApigeninGlucocorticoids

Autor:innen und Institutionen

  • Department of Pathology, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electroni…
  • Department of Biomedical Informatics, Center for Biostatistics, Pelotonia Institute of Immuno-Oncology, The Ohio State University, Wexner Medical Center, Columbus, OH, USA. Electronic address: xiaokui.mo@osumc.edu.

Förderung

  • American Cancer Society Inc
  • National Institutes of Health

Zitieren

APA

Lamenza, F. F., Upadhaya, P., Ramalingam, R., Jagadeesha, S., Shrestha, S., Kehres, R., Kazmierowicz, N., Dasari, S., Masood, S., Nyati, K. K., Roth, P., Horn, N., Pracha, H., Siddiqui, A., Mo, X., Zhu, J., Iwenofu, H., & Oghumu, S. (2026). Epithelial HSD11β2 as an immunometabolic checkpoint in head and neck cancer: Restoring local steroid inactivation reinvigorates T cell immunity. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218840

Vancouver

Lamenza FF, Upadhaya P, Ramalingam R, Jagadeesha S, Shrestha S, Kehres R, et al. Epithelial HSD11β2 as an immunometabolic checkpoint in head and neck cancer: Restoring local steroid inactivation reinvigorates T cell immunity. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218840

BibTeX
@article{Lamenza2026,
  author = {Lamenza, Felipe F and Upadhaya, Puja and Ramalingam, Ravi and Jagadeesha, Sushmitha and Shrestha, Suvekshya and Kehres, Reegan and Kazmierowicz, Natalie and Dasari, Sonali and Masood, Shaheer and Nyati, Kishan Kumar and Roth, Peyton and Horn, Natalie and Pracha, Hasan and Siddiqui, Arham and Mo, Xiaokui and Zhu, Jian and Iwenofu, Hans and Oghumu, Steve},
  title = {Epithelial HSD11β2 as an immunometabolic checkpoint in head and neck cancer: Restoring local steroid inactivation reinvigorates T cell immunity},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218840}
}
Kostenlos starten →